论文部分内容阅读
地高辛为临床常用的强心甙之一。因其治疗指数低，个体差异大，易产生药物中毒，特别在一些病理情况下，剂量很难掌握。为地高辛在临床上对甲状腺功能异常的心衰病人更为合理的使用，本实验用荧光偏振免疫分析方法，以犬为实验对象，研究了甲状腺机能亢进对地高辛体内过程的影响，结果表明：甲亢对地高辛体内过程有较大的影响，用成对数据资料ｔ检验对甲亢犬与正常犬中地高辛的药动学参数进行比较，甲亢犬中地高辛的机体清除率，由６．９７±１．４５Ｌ／ｈ增加到１３．８３±３．４９Ｌ／ｈ（Ｐ＜０．０１），消除半衰期由７．０２±１．５３ｈ减少到２．３２±０．０６ｈ（Ｐ＜０．０１），药时曲线下面积由７４．０４±１３．７４ｎｇ·ｈ·ｍｌ￣（－１）降至３７．９３±８．６２ｎｇ·ｈ·ｍｌ￣（－１）（Ｐ＜０．０１），达峰时间由３．７７±０．５９ｈ缩短为２．２６±０．５２ｈ（Ｐ＜０．０１），表观分布容积由７０．０９±１９．２０Ｌ减少到４６．８１±１８．２３Ｌ（Ｐ＜０．０１）。而吸收半衰期和滞留时间略有减小，峰浓度略有增加，但均未达到显著性差异（Ｐ＞０．０５）。
Digoxin is one of the commonly used cardiac glycosides. Because of its low therapeutic index, individual differences, easy to produce drug poisoning, especially in some pathological conditions, the dose is difficult to grasp. For digoxin in clinical thyroid dysfunction of heart failure patients more reasonable use of fluorescence polarization immunoassay in this experiment to dogs as the experimental object to study the effect of hyperthyroidism on the in vivo process of digoxin, The results showed that: hyperthyroidism has a greater impact on the in vivo process of digoxin, paired data t test was used to compare the pharmacokinetic parameters of digoxin in hyperthyroidism dogs and normal dogs, digoxin in hyperthyroidism dog body clearance Rate increased from 6.97 ± 1.45L / h to 13.83 ± 3.49L / h (P <0.01), and the elimination half-life decreased from 7.02 ± 1.53h to 2.32 ± 0.06h (P <0.01), and the area under the curve decreased from 74.04 ± 13.74ng · h · ml ~ (-1) to 37.93 ± 8.62ng · h · ml ~ (-1) (P <0.01), the peak time was shortened from 3.77 ± 0.59h to 2.26 ± 0.52h (P <0.01), and the apparent volume of distribution increased from 70.09 ± 19.2 L decreased to 46.81 ± 18.23L (P <0.01). The absorption half-life and residence time decreased slightly, while the peak concentration increased slightly, but did not reach significant difference (P> 0.05).